UCB (OTCMKTS:UCBJY) Sets New 1-Year High - Still a Buy?

Key Points

• UCB SA shares reached a new 52-week high, trading at $113.85, reflecting growing investor interest with a volume of 16,384 shares.
• Goldman Sachs upgraded UCB to a "strong-buy" rating, indicating positive sentiment and potential growth for the stock.
• The company specializes in neurology and immunology treatments, with notable products including Cimzia and Vimpat, which cater to various chronic conditions.

UCB SA (OTCMKTS:UCBJY - Get Free Report) reached a new 52-week high during trading on Friday . The company traded as high as $113.85 and last traded at $112.97, with a volume of 16384 shares traded. The stock had previously closed at $113.27.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group upgraded UCB to a "strong-buy" rating in a research report on Wednesday, July 16th. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, UCB presently has a consensus rating of "Strong Buy".

UCB Stock Up 1.6%

The company has a 50 day moving average price of $102.02 and a 200 day moving average price of $94.77. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.36 and a quick ratio of 0.99.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.